A noncovalent soft elastomer includes a binary block copolymer composed of an A block and a B block and a solvent, wherein the B block has a noncovalent-bonding functional group, and the solvent is a nonvolatile liquid which has a property of dissolving the B block but not dissolving the A block and which forms a functional group capable of noncovalent-bonding of the B block.

Provided is a surface treatment agent which does not use fluorine-containing monomers, particularly fluoroalkyl group-containing monomers. Additionally, provided is a copolymer which includes a first polymer formed from first monomers, and a second polymer formed from second monomers. The copolymer does not include fluorine. The second polymer is polymerized in the presence of the first polymer. The first monomers include a long-chain acrylate ester monomer (a) represented by the formula CH.sub.2=CA.sup.11-C(O)O-A.sup.12 (in the formula, A.sup.11 represents hydrogen, a monovalent organic group, or a halogen, and A.sup.12 represents a C.sub.18-30 straight-chain or branched hydrocarbon group). The first monomers and the second monomers both include a halogenated olefin monomer (b).

The present invention generally relates to processes for converting an ester group to an acid group for polymers having a pendant ester of an acid group. This process is generally performed using an aqueous strong base.

The present invention generally relates to processes for converting an ester group to an acid group for polymers having a pendant ester of an acid group. This process is generally performed using an aqueous strong base.

An ophthalmic device is disclosed that is a polymerization product of a monomeric mixture comprising: (a) a major amount of one or more non-silicone-containing hydrophilic monomers; (b) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group, and (c) one or more hydrophilic polymers or copolymers comprising one or more hydrophilic units and a thio carbonyl thio fragment of a reversible addition fragmentation chain transfer (RAFT) agent wherein the ophthalmic device has an equilibrium water content of at least about 45 weight percent.

This invention relates to rapid prototyping systems, specifically, a continuous moving surface liquid resin system (CMSL) and fast printing method for making any 3D objects, such as dental devices, including but not limited to artificial teeth, dentures, orthodontic appliances, aligners, splints, veneers, inlays, onlays, copings, frame patterns, crowns and bridges and the like. 3D printers, such as DLP or stereolithography printer, are used to cure polymerizable material in a layer-by-layer manner to build-up the object rapidly and continuously.

This invention relates to rapid prototyping systems, specifically, a continuous moving surface liquid resin system (CMSL) and fast printing method for making any 3D objects, such as dental devices, including but not limited to artificial teeth, dentures, orthodontic appliances, aligners, splints, veneers, inlays, onlays, copings, frame patterns, crowns and bridges and the like. 3D printers, such as DLP or stereolithography printer, are used to cure polymerizable material in a layer-by-layer manner to build-up the object rapidly and continuously.

The present invention generally relates to processes for converting an ester group to an acid group for polymers having a pendant ester of an acid group. This process is generally performed using an aqueous strong base.

The present invention generally relates to processes for converting an ester group to an acid group for polymers having a pendant ester of an acid group. This process is generally performed using an aqueous strong base.

An ophthalmic device is disclosed that is a polymerization product of a monomeric mixture comprising: (a) a major amount of one or more non-silicone-containing hydrophilic monomers; (b) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group, and (c) one or more hydrophilic polymers or copolymers comprising one or more hydrophilic units and a thio carbonyl thio fragment of a reversible addition fragmentation chain transfer (RAFT) agent wherein the ophthalmic device has an equilibrium water content of at least about 45 weight percent.